A multiplex PCR assay for the simultaneous detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis*

Ahmad N. Abou Tayoun a,b, Paul R. Burchard a,b, Angela M. Caliendo c, Axel Scherer d, Gregory J. Tsongalis a,b,*

a Department of Pathology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States
b Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH, United States
c Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, United States
d Department of Electrical Engineering, California Institute of Technology, Pasadena, CA, United States

ARTICLE INFO

Keywords:
Chlamydia
Neisseria
Trichomonas
PCR

ABSTRACT

Introduction: For developing countries, sexually transmitted infections (STIs) and their complications are ranked in the top 5 disease categories for which adults seek medical treatment. *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG), and *Trichomonas vaginalis* (TV) are the three most common STIs worldwide, with TV accounting for over half of the cases. In developing countries, traditional methods for diagnosing STIs are laborious, often not very sensitive, and have a long turnaround time with most recent commercially available diagnostic tests targeting one or, at most, two of these STIs at a time. Here, we describe the development of a highly sensitive, rapid and affordable sample-to-answer multiplex PCR-based assay for the simultaneous detection of *Trichomonas vaginalis*, *Neisseria gonorrhoeae*, and *Chlamydia trachomatis*.

Materials and Methods: We designed a multiplex PCR assay for the detection of 4 targets (CT, TV, NG, and process/PCR control) using melt curve analysis. To establish the limit of detection (LOD) for each pathogen, we used previously extracted and quantified TV, NG, and CT genomic DNA (Vircell, Spain). For each target, the LOD was determined by lowering its copy number while increasing the other two STI loads in a stepwise fashion. The process/PCR control remained constant in the optimized assay and was spiked into each sample before extraction. For a concordance study, we tested urine, vaginal and rectal swab specimens from 26 patients positive for one or more of the tested STIs. In addition, 56 liquid cytology specimens (Thinprep) were used to assess specificity. Results: This assay has a turnaround time of less than 2 h and has a limit of detection as low as 7–31 copies for each STI in the presence of the other 2 targets. Our assay also demonstrated 100% concordance with 26 known clinical samples from urine, vaginal and rectal swab specimens. TV, NG, CT, and our process/PCR control were consistently identified at 78 °C, 82.3 °C, 85.7 °C, and ~92 °C, respectively. When applied to DNA extracted from residual Thinprep specimens, the assay was negative in 54/56 samples. Two samples were found to be co-infected with CT.

Conclusions: Our multiplex assay combines a rapid and cost-effective approach to molecular diagnostics with the versatility required for use within a variety of laboratory settings. These performance characteristics make this multiplex STI assay highly suitable for use in a clinical laboratory.

© 2015 Elsevier Inc. All rights reserved.

1. Introduction

An estimated 499 million new cases of curable sexually transmitted infections (STIs) occur every year, with around 19 million in the United States alone (http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/sexually-transmitted-diseases; http://www.who.int/mediacentre/factsheets/fs510/en/index.html; Owusu-Edusei et al., 2013; Chesson et al., 2004). For developing countries, STIs and their complications are ranked in the top 5 disease categories for which adults seek medical treatment (http://www.who.int/mediacentre/factsheets/fs110/en/index.html; Diclemente et al., 2004). *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG), and *Trichomonas vaginalis* (TV) are the three most common STIs worldwide, with TV accounting for over half of the cases (http://www.cdc.gov/std/stats10/default.html; Manam et al., 2013; Coleman et al., 2013; Mahony et al., 1995; Blake et al., 2008). Such STIs often appear asymptomatic and, if untreated, can have devastating consequences on reproduction, maternal and newborn health, as well as increase the likelihood of acquisition and transmission of HIV (http://www.cdc.gov/std/stats10/default.html; Katusiime et al., 2013; Gottlieb et al., 2013; Theunissen et al., 2013; Al-Moushaly, 2013; Beharry et al., 2013). The World Health Organization (WHO) has identified rapid, low-cost, and accurate point-of-care diagnostic tests as a key point for action in the global strategy for the prevention and control
Trichomonas vaginalis

2. Materials and methods

2.1. Samples

A total of 83 patient samples were used in this study. In the concordance study, 26 samples including 10 urine, 9 vaginal and 7 rectal swab specimens were obtained from patients that have previously tested positive for CT and NG using the Abbott m2000 real-time CT/NG assay, and TV using a laboratory developed Real-Time PCR assay (Caliendo et al., 2005). For the sensitivity study, limit of detection was established using genomic DNA extracted from known numbers of TV, NG, and CT organisms (Vircell, Spain). For the specificity study, we used 57 female patient samples previously tested for Human Papillomavirus (HPV) with the Roche COBAS® 4800 HPV Assay.

2.2. Extraction

For each patient sample, 2 ml (urine) or 600 μl buffer (swabs) was pelleted by centrifugation at 6000 rpm for 10 min and re-suspended with 195 μl of water. Each sample was then spiked with 5 μl of 2.5 pg/μl internal control DNA (IC2M, see Table 1). DNA was then extracted with the Qiagen EZ1 robotic system using the bacterial DNA card and the EZ1 tissue extraction kit/cartridges (Qiagen, Valencia, CA). DNA was eluted in 50 μl elution buffer, of which 10 μl was used for the 25 μl PCR reactions.

3. Results

3.1. Multiplex STI assay

Our PCR-based assay was developed for the simultaneous detection of three major STIs (CT, NG, and TV) in addition to a novel internal control DNA sequence (IC2M). The latter was spiked into each patient sample before extraction and thus served as both a process and PCR control (see Materials and methods). All primer sequences were carefully designed and selected to clearly resolve the characteristic intercalating dye-based melt peaks for the four different targets in our multiplex assay (Fig. 1B). In our primer design, we targeted multi-copy regions within the three STI genomes to achieve highest sensitivity. For

<table>
<thead>
<tr>
<th>Oligo name</th>
<th>Sequence</th>
<th>Target</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Internal control (IC2M)</td>
<td>TGTATACCGTACGACCAAATTCGCCAGGTTACTTAGCAGGTCGTAC</td>
<td>NA</td>
<td>Modified from Spinacia oleracea chloroplast ribulose 1,5-bisphosphate carboxylase small subunit gene (GenBank: L776557.1)</td>
</tr>
<tr>
<td>IC2M forward</td>
<td>5’-GCTGGAATAGGCGAAAGT-3’</td>
<td>IC2M</td>
<td>In-house</td>
</tr>
<tr>
<td>IC2M reverse</td>
<td>5’-GAATGGCTACGTTAAGATC-3’</td>
<td>IC2M</td>
<td>In-house</td>
</tr>
<tr>
<td>CT forward</td>
<td>5’-TCTGACACCTAGGCTTCT-3’</td>
<td>Crystalline pseudogenes</td>
<td>In-house</td>
</tr>
<tr>
<td>CT reverse</td>
<td>5’-CGTATCCGTTACGTCGTT-3’</td>
<td>porA pseudogenes</td>
<td>Anon. (2007)</td>
</tr>
<tr>
<td>NG forward</td>
<td>5’-CCGAACTGGTTCTCAGT-3’</td>
<td>2-kb repeated target</td>
<td>Anon. (2006)</td>
</tr>
<tr>
<td>NG reverse</td>
<td>5’-TCTGACACCTAGGCTTCT-3’</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TV forward</td>
<td>5’-AAGATGGGTGCTTGAAGTTAAGATG-3’</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TV reverse</td>
<td>5’-CCGAACTGGTTCTCAGT-3’</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Chlamydia trachomatis, we targeted the multi-copy cryptic plasmid thus, not only enhancing sensitivity, but also ensuring the detection of all Chlamydia trachomatis serovars including the Swedish nvCT serovar (Caliendo et al., 2005; Palmer and Falkow, 1986; Unemo & Clarke, 2011). After extensive PCR optimization, we devised a touchdown PCR protocol with extension temperatures gradually decreasing from 70 °C to 60 °C as shown in Fig. 1A. With this optimal protocol, we were able to precisely resolve the melt peaks for TV at 78 °C, NG at 82.3 °C, CT at 85.7 °C, and IC2Ma t9 2° C (Fig. 1B).

3.2. Sensitivity or limit of detection

To establish the limit of detection (LOD) for each pathogen, we spiked into our PCR reactions genomic DNA extracted from known copy numbers of TV, NG, and CT (Vircell, Spain). For each target, the LOD was determined by lowering its copy number while increasing the other two STI loads in a stepwise fashion (Tables 2–4). For example, the LOD for Neisseria gonorrhoeae was 7 or 15 copies/reaction even when either TV or CT was present at a high concentration (3000 copies/reaction), respectively. This LOD was increased to 31 copies/reaction when both TV and CT were each present at 3000 copies/reaction (Table 2 and Fig. 2). Although the LOD for either TV or CT was 7 copies/reaction in the absence of the other two pathogenic targets, this LOD ranged between 7 and 31 copies/reaction as the other STIs were increasingly spiked (up to 3000 copies) into the PCR reaction (Tables 3 and 4). Overall, our assay demonstrates a very high sensitivity for the detection of each of the STI targets even when the other targets were present at very high copy numbers.

3.3. Specificity

We assessed the specificity of the assay by testing specimens which had been previously submitted for HPV screening. We extracted DNA from 56 female patient Thinprep liquid cytology specimens. Twelve of these specimens were positive for high risk HPV. Of the 12 positive HPV samples, we identified 2 as also positive for CT. This was not a surprising finding as co-infection of HPV and CT occurs in approximately 14% of HPV positive women (Verteboom et al., 2009), which is

---

**Table 2**

<table>
<thead>
<tr>
<th>Chlamydia trachomatis (LOD)</th>
<th>Neisseria gonorrhoeae</th>
<th>Trichomonas vaginalis</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>7 High*</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>15 High†</td>
<td>0</td>
<td>High</td>
</tr>
<tr>
<td>31 High</td>
<td>High</td>
<td>High</td>
</tr>
</tbody>
</table>

* 7 copies per reaction.
† 3000 copies per reaction.

**Table 3**

<table>
<thead>
<tr>
<th>Neisseria gonorrhoeae (LOD)</th>
<th>Chlamydia trachomatis</th>
<th>Trichomonas vaginalis</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>7 Low*</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>15 High†</td>
<td>0</td>
<td>High</td>
</tr>
<tr>
<td>31 High</td>
<td>High</td>
<td>High</td>
</tr>
</tbody>
</table>

* 7 copies per reaction.
† 3000 copies per reaction.
consistent with our findings. The other HPV positive samples as well as the 44 HPV negative samples showed only amplification of the internal control. This suggests proper DNA extraction and no cross reactivity between positive HPV samples or genomic DNA with our assay. In addition, we tested positive gram-positive and gram-negative bacteria samples representing normal vaginal flora. Our assay identified all ten of these bacteria samples as negative for our STI targets, which was expected. This suggests no cross reactivity between our assay and common vaginal flora.

Furthermore, of the 26 known positive swab and urine samples (see below), our assay never gave an unexpected melt peak for any of the tested targets. This further supports our primer sets as specific for each target and that they do not cross react with one another or the internal control, even at high concentrations.

3.4. Accuracy

To determine the accuracy of our assay, we extracted DNA from 26 samples for patients previously shown to be positive for CT, NG, and/or TV and tested them using our assay. The specimens used for this accuracy study were from urine, vaginal swabs, and rectal swabs. Our assay correctly identified 26 of the 26 previously tested patient samples. TV and CT infections were found in 8 samples and NG infection was found in 6 samples. Co-infections with CT and TV, NG and TV, and CT and NG, were found in 1 sample each. These results were 100% concordant with what was expected and demonstrate a high level of accuracy for our assay from a variety of specimen sources.

3.5. Turnaround time

The total turnaround time for this assay is less than 2 h. The assay begins with a 10 minute centrifugation, followed by a 15 minute automated extraction. PCR amplification takes approximately 1 h to set up and run. The results of the melt-curve are available within a few minutes of completion of the amplification and easy to interpret.

Table 4

<table>
<thead>
<tr>
<th>Trichomonas vaginalis (LOD)</th>
<th>Chlamydia trachomatis</th>
<th>Neisseria gonorrhoeae</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>15</td>
<td>High*</td>
<td>0</td>
</tr>
<tr>
<td>15</td>
<td>High</td>
<td>High</td>
</tr>
</tbody>
</table>

* 7 copies per reaction.

b 3000 copies per reaction.

Fig. 2. SmartCycler real-time PCR melt curve analysis results for Neisseria gonorrhoeae (NG) limit of detection. Plotted as the fluorescence with respect to temperature. Copy number refers to the copies of NG in the reaction mixture. High Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV) correspond to 3000 copies of each in the reaction mixture.
4. Discussion

In this study, we report proof of principle for a new multiplex method for the simultaneous detection of the three most common STIs; TV, CT, and NG from various specimen sources including Thinprep liquid cytology samples. This multiplex PCR-based assay uses an intercalating dye and melt–curve analysis to determine the presence of each STI. Such an assay can be made affordable, highly sensitive and can be performed on real-time PCR platforms common to any molecular diagnostics laboratory. Multiplexing provides the advantage of detecting multiple targets at the same time and from the same specimen. Furthermore, the ability to limit the diagnostic process to one test minimizes both cost and time.

Unlike fluorescently labeled probes, the use of intercalating dyes and melt curve analysis greatly lowers the cost of this assay while maintaining high specificity and sensitivity. Our assay also uses an automated DNA extraction system, which minimizes the required hands-on time. This not only limits the possibility of contamination but also makes for a safer extraction process. The turnaround time for our assay is less than 2 h, which drastically reduces the turnaround time as compared to more traditional culture based methods.

Our results demonstrate this assay as highly sensitive, specific, and accurate. The LOD for this assay was very low for each STI, even in the presence of high copy numbers of one or both of the other STIs. Our assay will therefore be able to easily identify co-infection amongst all three of these STIs. In addition, our results were 100% concordant with what was expected for the previously tested patient specimens. Specimens containing one or more of the desired STIs were equally identifiable, which was expected. In addition, these specimens exhibit the wide range of samples that can be used in our assay, such as urine, vaginal swabs, and cervical cytology specimens.

This assay combines a rapid and cost-effective approach to molecular diagnostics with the versatility required for use within a variety of laboratory settings. These performance characteristics make this multiplex STI assay highly suitable for use in a clinical laboratory.

Acknowledgments

The authors would like to thank Cheryl Bissaillon from the Baystate Health Center for generously providing control samples. The authors wish to thank the staff of the DHMC Molecular Pathology Laboratory and the Translational Research Program. The data presented in this manuscript was in part generated through the Department of Pathology Translational Research Shared Resource Laboratory of the Geisel School of Medicine at Dartmouth, the Dartmouth Hitchcock Medical Center and the Norris Cotton Cancer Center. This work was supported by the Bill and Melinda Gates Foundation [Global Health Grant Number OPP1028794].

References